|
|
 | |
- close
- close
United Therapeutics (UTHR) |
StreetInsider.com
Jul 28
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/United+Therapeutics+%28UTHR%29+Posts+Q2+EPS+of+%240.67%2C+Beats+Views/5840317.html for the full story.
PR Newswire
Jul 28
Comment
SILVER SPRING, Md., July 28 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $137.5 million, up
PR Newswire
Jul 21
Comment
SILVER SPRING, Md., July 21 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will release its second quarter 2010 financial results before market open on Wednesday, July 28, 2010. United Therapeutics
PR Newswire
Jul 1
Comment
SILVER SPRING, Md., July 1 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) and Lee's Pharmaceutical Holdings Ltd. (HKEx: 0950) announced today that they have entered into an exclusive agreement for the distribution of
Market Intelligence Center
Jun 10
Comment
United Therapeutics (UTHR) was upgraded today by analysts at JP Morgan and the stock is now at $53.81, up $2.31 (4.49%) on volume of 494,000 shares traded. The stock was upped to Overweight from Neutral. Over the last 52 weeks the stock has ranged...
Stock Blog Hub
May 6
Comment
United Therapeutics Corp. (UTHR) reported first-quarter profit of 32 cents per share, a couple of cents above the Zacks Consensus Estimate and 28% above the year-ago earnings of 25 cents. A huge boost in revenues helped drive earnings despite an...
StreetInsider.com
Apr 29
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/United+Therapeutics+%28UTHR%29+Posts+Q1+EPS+of+%240.35%2C+Beats+Views+by+6c/5576070.html for the full story.
newratings.com
Apr 28
Comment
NEW YORK, April 29 (newratings.com) - Analysts at RBC Capital initiate coverage of United Therapeutics Corporation (ticker: UTHR) with a "market outperform" rating. The target price is set to $66. [more]
StreetInsider.com
Apr 5
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Upgrades/Summer+Street+Upgrades+United+Therapeutics+%28UTHR%29+to+Buy%3B+Evidence+of+Continued+Strong+Tyvaso+Rollout/5501175.html for the full story.
StreetInsider.com
Feb 19
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/United+Therapeutics+%28UTHR%29+Withdraws+MAA+for+Tyvaso+from+European+Medicines+Agency/5365144.html for the full story.
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
 |
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article. |
References
| ||||||
